Empatica

Empatica operates at the intersection of regulated medical wearables, digital biomarkers, remote patient monitoring, and clinical-trial technology. Its differentiation is the integration of hardware, cloud software, physiological signal collection, and AI-derived measures rather than a single-purpose consumer wearable. EmbracePlus and EmbraceMini target research and decentralized clinical-trial workflows, while EpiMonitor addresses epilepsy monitoring and the company’s FDA-cleared Parkinson’s platform extends its reach into neurological care. The business also combines affective-computing heritage with medical-device and clinical-research capabilities, supported by leadership linked to MIT and major healthcare institutions. Empatica’s regulatory progress, including MDR certification in 2025 and FDA clearance in 2026, provides a stronger clinical-market signal than consumer wellness devices, but its position remains dependent on converting validated sensor data and digital biomarkers into reimbursable care, trial, and pharmaceutical use cases.

Empatica’s trajectory shows a shift from early wearable commercialization toward a broader regulated health-monitoring platform. The company raised $2.0 million in Seed funding in 2014, $780,000 through product crowdfunding in 2015, and $5.0 million in a 2016 Series A, followed by an undisclosed 2017 venture round and a further $1.89 million Series A in 2020. Its largest disclosed financing was a $25.95 million Series B on Aug 2, 2022, bringing total funding to $35.62 million across six rounds. Product expansion has continued through EmbracePlus, Empatica Care, EpiMonitor, and the 2025 launch of EmbraceMini. Regulatory milestones are important inflection points: EpiMonitor gained MDR certification in June 2025, and Empatica received FDA clearance for Parkinson’s monitoring in August 2026. The 2025 acquisition of PKG Health adds movement-disorder algorithms and digital endpoints. Hiring activity and reported 70% team growth in 2022 suggest organizational scaling, while the absence of disclosed post-2022 financing leaves the pace of capital expansion unclear.